Browse the evidence

In patients with cardiometabolic HFpEF, semaglutide showed a 42% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.

Semaglutide may be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.

Tirzepatide showed no meaningful benefit over semaglutide in reducing the risk of hospitalization for heart failure or all-cause mortality.

Clinicians may consider semaglutide as the preferred option over tirzepatide for this patient population.

Greater male variation in basal energy expenditure may be explained by greater male variation in the size of energy-demanding organs.

Understanding organ size variation may help tailor nutritional strategies for energy expenditure.

The number of adults with diabetes globally increased from 108 million in 1980 to 422 million in 2014.

Healthcare practitioners should be aware of the significant increase in diabetes prevalence when planning interventions.

Worldwide age-standardized adult diabetes prevalence doubled from 4.3% to 9.0% in men and from 5.0% to 7.9% in women.

This information is crucial for public health initiatives targeting diabetes prevention and management.

Few companies in the US reduced portion sizes of ultra-processed foods since 2002.

Practitioners should be aware that portion sizes of ultra-processed foods have not decreased significantly, which may impact dietary recommendations.

The safety of retatrutide needs to be determined in larger and longer trials.

Practitioners should be aware that more extensive safety data is needed before fully endorsing retatrutide.

Metformin failed to prove beneficial effects in MASLD progression.

Avoid using metformin for treating MASLD progression as it has not shown benefits.

Adipocyte and preadipocyte formation in scABD and scFEM depots correlates positively with VAT/TAT.

Understanding the relationship between adipocyte formation and VAT/TAT can inform strategies for managing obesity.

BAT thermal activity does not change in response to overfeeding.

Overfeeding does not affect BAT thermal activity in men.

BAT thermal activity does not correlate with the degree of metabolic adaptation.

BAT activity does not influence metabolic adaptation to overfeeding.

Glucose is essential for the functioning of the pentose phosphate pathway (PPP) and cannot be substituted by other metabolites.

Practitioners should recognize the critical role of glucose in metabolic pathways.

The incidence of completed or attempted suicide and occurrences of suicidal ideation or self-harm is very low in individuals receiving GLP-1 receptor agonists (0.047 per 100 person-years) compared to placebo (0.042 per 100 person-years), with no statistically significant difference.

Practitioners can be reassured that GLP-1 RAs do not appear to increase the risk of suicidality in their patients.

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving GLP-1 receptor agonists within the context of randomized controlled trials.

Healthcare providers can continue to prescribe GLP-1 RAs without heightened concern for suicidality in clinical settings.

Expanded Medicare coverage for GLP-1 receptor agonists (GLP-1RAs) for obesity treatment is projected to increase total Medicare drug costs by $65.9 billion over 10 years.

Practitioners should be aware of the significant projected costs associated with GLP-1RA coverage under Medicare.

The net increased spending due to expanded Medicare coverage for GLP-1RAs is projected to be $47.7 billion over 10 years.

Practitioners should be aware of the substantial net spending implications of GLP-1RA coverage.

Semaglutide improves the function and inflammatory status of endothelial progenitor cells (EPCs) by inhibiting LPS-induced macrophage expression of miR-155 in exosomes.

Semaglutide may be beneficial in improving endothelial function in obesity-related inflammation.

LPS-induced macrophage exosomes reduce the cellular activity, migratory capacity, and tube-forming ability of EPCs.

Inflammation from macrophage exosomes can impair endothelial repair mechanisms.

Inhibition of miR-155 expression in macrophages improves EPC viability and reduces inflammation.

Targeting miR-155 may be a therapeutic strategy to enhance endothelial repair in obesity.

Semaglutide alleviated metabolic disorders, ameliorated myocardial fibrosis, improved cardiac function, antagonized oxidative stress, and suppressed cardiomyocyte apoptosis in diabetic mice.

Semaglutide may be beneficial for improving heart health in diabetic patients.

Semaglutide attenuated cardiac inflammation through restoring RKIP expression and inhibiting the TBK1-NF-κB pathway.

Understanding this mechanism can help in developing targeted therapies for cardiac inflammation in diabetes.

Semaglutide's anti-inflammatory effect is mediated through the Sirt3-dependent RKIP pathway, rather than glucose lowering.

This suggests that semaglutide may have benefits beyond just lowering blood sugar in diabetic patients.

Patients prescribed semaglutide or tirzepatide had an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) with a hazard ratio of 1.76.

Clinicians should monitor patients on semaglutide or tirzepatide for signs of NAION.

Patients prescribed semaglutide or tirzepatide had an increased risk of other optic nerve disorders with a hazard ratio of 1.65.

Clinicians should be aware of the risk of other optic nerve disorders in patients on semaglutide or tirzepatide.